A novel collaboration breaks ground with an inhaled mRNA therapy entering early clinical testing for the first time—a …
A novel collaboration breaks ground with an inhaled mRNA therapy entering early clinical testing for the first time—a …
Generative AI has produced a novel TNIK-inhibiting compound now advancing in phase 2a trials—an unprecedented milestone in drug discovery.
A landmark U.S. FDA nod for Datopotamab deruxtecan (Datroway) marks a promising advance for treating metastatic HR‑positive, HER2‑negative …
Neumora Therapeutics sees its share value collapse as its lead antidepressant candidate, navacaprant, fails to outperform placebo in …
A pivotal agreement between uniQure and the FDA ignites momentum for Huntington’s gene therapy, while Europe’s regulatory landscape …
CMS approval of Tempus’s AI-powered ECG‑AF algorithm marks its inclusion under U.S. Medicare reimbursement, enabling broader access to …
As 2024 wraps up, end-of-year research highlights—from AI-driven disease detection to expanded diagnoses and novel trial milestones—are shaping …
As traditional VC investment remains selective, firms like Abingworth and Vie Ventures are pioneering fresh approaches—launching billion-dollar trials …
The NHS is set to trial an AI-based solution that can forecast type 2 diabetes risk by analyzing …
Late-December 2024 sees the launch of Australia’s first government-backed clinical trial using AI-guided neuromodulation to tackle severe, treatment-resistant …
